New drug cocktail aims to shrink lung tumors before surgery

NCT ID NCT07438600

Not yet recruiting Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether combining two drugs—sacituzumab tirumotecan and toripalimab—given before surgery can shrink tumors in people with stage II to IIIB non-small cell lung cancer (NSCLC). About 38 participants will receive the drugs intravenously over several weeks, then have surgery to remove any remaining cancer. The main goal is to see how many patients have no cancer left in their lung tissue after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sacituzumab tirumotecan (a targeted antibody-drug conjugate) combined with toripalimab (an immunotherapy drug)
What this could lead to: If successful, this combination could become a new pre-surgery treatment option for certain non-small cell lung cancers, potentially improving tumor shrinkage and long-term outcomes.
What could go wrong: This is a small, early-phase trial with only 38 participants, so results may not apply broadly. The drugs can cause serious side effects like immune-related reactions or low blood cell counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (NON-SMALL CELL LUNG CANCER)

More trials for these conditions

Other studies related to the condition(s) this trial covers.